Pfizer Enters Gene-Editing Pact With Beam Therapeutics

Pfizer is set to pay $300 million up front in a milestone deal with Beam Therapeutics, the pioneer of a new gene-editing approach called base editing.

Related Keywords

,Bi Prime ,Healthcare ,Gene Editing ,Pfizer ,Beam Therapeutics ,Rispr ,Base Editing ,Harmaceutical ,Biotech ,Ufi Photos ,Ispensed ,Insider Healthcare ,Andrew Dunn ,